Crocker, I; Waksman, R

Novoste licensed Emory technology to develop the Beta-Cath™ System in the field of vascular brachytherapy (VBT) - radiation therapy delivered inside an artery to prevent it from re-closing (restenosis). Restenosis occurs when scar tissue grows inside an artery and limits blood flow after procedures such as angioplasty, often resulting in the need for additional procedures to re-open the vessel.

The Beta-Cath™ System received marketing approval from the U.S. Food and Drug Administration (FDA) in November, 2000, and was the first commercially available vascular brachytherapy device in both the United States and Europe. Over 20,000 patients have been treated worldwide with the Novoste™ Beta-Cath™ System. The Beta-Cath™ System has been approved by the FDA for use in patients suffering from in-stent restenosis, a condition in which coronary stents become blocked with new tissue growth. Before vascular brachytherapy, there were no effective treatments for in-stent restenosis other than bypass surgery, an expensive and highly invasive procedure.